Biomarkers Market Accrues Phenomenally by 2026 with a Staggering CAGR

76

Summary

The Biomarkers Market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025)

Press Release

The Biomarkers Market is estimated to be valued at US$ 29,518.2 Mn in 2017 and is expected to witness a robust CAGR of 13.6% during the forecast period (2017-2025).

Biomarkers are used for diagnosis and drug development, as these biomarkers can indicate diseases in the body. Furthermore, biomarkers can be any specific cells, molecules, genes or gene products, enzymes or hormones. Biomarker-based test are precise and rapid, which help in early prediction of susceptibility, prognosis, diagnosis, and treatment of disease. Hence, increasing research and development activities for identifying new biomarkers to diagnose or treat diseases is expected to be major factor growth of the market.

Market Dynamics

The global biomarkers market is projected to witness significant growth over the forecast period, owing to rapid advancements in technology for development of novel biomarker. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury named Banyan BTI. Such innovations, targeting different indications, is expected to drive biomarkers market growth in the near future.

Biomarkers are gaining significant traction in product development and treatment of disorders related to chromosome structure, Turner syndrome, Down syndrome, Patau syndrome, Edwards’s syndrome, and others, which is propelling demand for biomarkers. For instance, in February 2018, FDA granted marketing authorization to Banyan Biomarkers, Inc. for the first diagnostic blood test for traumatic brain injury, Banyan BTI. Therefore, introduction of such innovative diagnostic tools for various disease indication is projected to fuel growth of the biomarkers market over the forecast period.

Competitive Analysis

Key players are involved in new product launches to cater to increasing demand for biomarkers. For instance, in 2016 Abbott Laboratories launched Point-of-Care i-STAT Alinity, an innovative, handheld blood testing platform. Some of the other key players in biomarkers market include Medtronic plc, BG Medicine, Inc., F. Hoffmann-La Roche Ltd., Seimens Healthnineers, Nexus-DX, Qiagen N.V., and Lifesign LLC.

Increasing demand for precision medicine to drive the growth of the global biomarkers market

North America accounts for the largest share in the global biomarkers market and this is attributed to adoption of precision medicine and growing prevalence of cancer in the region. According to the National Cancer Institute, 2016, it was estimated that 16.8 million new cases of cancer were diagnosed in the U.S., with around 595,690 deaths from cancer disease. The number of people suffering from cancer is expected to rise to 19 million by 2024, which supports increasing demand for precision medicine.